Lincoln Pharmaceuticals Upgraded to 'Hold' Rating by MarketsMOJO, Attractive Valuation and Institutional Investor Confidence Boost Stock

Nov 16 2024 08:45 AM IST
share
Share Via
Lincoln Pharmaceuticals, a smallcap pharmaceutical company, has been upgraded to a 'Hold' rating by MarketsMojo due to its stable financial position with a low Debt to Equity ratio. The stock's technical trend is currently sideways, but its attractive valuation, rising profits, and increasing institutional investor participation make it a good investment opportunity. However, the company has shown poor long-term growth and has underperformed the market in the past year. Investors should carefully evaluate before investing.
Lincoln Pharmaceuticals Upgraded to 'Hold' Rating by MarketsMOJO, Attractive Valuation and Institutional Investor Confidence Boost Stock
Lincoln Pharmaceuticals, a smallcap pharmaceutical company, has recently been upgraded to a 'Hold' rating by MarketsMOJO on November 16, 2024. This upgrade comes as the company has shown a low Debt to Equity ratio of 0 times, indicating a stable financial position. The technical trend for the stock is currently sideways, with no clear price momentum. However, it has improved from a mildly bearish trend on November 13, 2024, and has generated a return of -1.03% since then.
One of the key factors contributing to the 'Hold' rating is the company's attractive valuation. With a ROE of 15.1 and a price to book value of 1.9, the stock is trading at a discount compared to its historical valuations. Additionally, the company's profits have risen by 19.6% in the past year, while the stock has generated a return of 3.39%. This has resulted in a PEG ratio of 0.7, indicating a good investment opportunity. Another positive aspect for Lincoln Pharmaceuticals is the increasing participation of institutional investors. These investors have increased their stake by 1.2% in the previous quarter and now collectively hold 5.19% of the company. This shows their confidence in the company's fundamentals and potential for growth. However, the company has shown poor long-term growth with net sales growing at an annual rate of 9.86% and operating profit at 13.70% over the last 5 years. In the latest quarter, the company's ROCE (HY) was at its lowest at 19.61%, and its PBT LESS OI (Q) has fallen by -11.99%. This may be a cause for concern for investors. In the last 1 year, Lincoln Pharmaceuticals has underperformed the market, generating a return of only 3.39% compared to the market (BSE 500) returns of 26.29%. This could be due to various factors, including the overall market conditions and the company's performance. Overall, with a 'Hold' rating, Lincoln Pharmaceuticals shows potential for growth but also has some areas of concern. Investors should carefully consider their options before making any investment decisions.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Why is Lincoln Pharmaceuticals Ltd falling/rising?
Feb 04 2026 01:07 AM IST
share
Share Via
Lincoln Pharmaceuticals Ltd is Rated Sell
Feb 03 2026 10:14 AM IST
share
Share Via
Lincoln Pharmaceuticals Ltd is Rated Sell
Jan 23 2026 10:10 AM IST
share
Share Via